Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood (2009) 2.82

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol (2001) 2.20

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood (2012) 2.12

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol (2007) 1.93

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol (2008) 1.68

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65

Dermatologic toxicities of targeted anticancer therapies. J Support Oncol (2010) 1.53

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol (2008) 1.39

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33

Hand-foot and stump syndrome to sorafenib. J Clin Oncol (2007) 1.17

The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol (2006) 1.03

Docetaxel-induced Hand and Foot Syndrome in a Patient with Metastatic Breast Carcinoma. Indian J Dermatol (2013) 0.91